Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

This study has been completed.

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00103922

Purpose

This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)

Condition	Intervention	Phase
Emphysema Bronchitis	Drug: cilomilast	Phase III

MedlinePlus related topics: Bronchitis COPD (Chronic Obstructive Pulmonary Disease) Emphysema

Drug Information available for: Cilomilast

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	600
Study Start Date:	November 2004

Eligibility

Criteria

Inclusion criteria:

Exclusion criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00103922

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MD

GlaxoSmithKline

More Information

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	CIL103657
Study First Received:	February 17, 2005
Last Updated:	October 13, 2008
ClinicalTrials.gov Identifier:	NCT00103922
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

smokers cough

Study placed in the following topic categories:

Pulmonary Emphysema
Emphysema
Lung Diseases, Obstructive
Respiratory Tract Infections
Respiratory Tract Diseases

Lung Diseases
Cough
Bronchitis
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Pathologic Processes
Bronchial Diseases

ClinicalTrials.gov processed this record on January 15, 2009